Views & Analysis Coming of age: Alnylam and the RNAi revolution Alynylam has a crucial two years ahead of it, but it and RNAi could be about to come of age.
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
